Skip to Main Content

Terence W. Friedlander


Genitourinary oncologist
Medical oncologist who loves to travel and play tennis

Dr. Terence Friedlander specializes in cancers of the genital and urinary organs, in particular bladder and prostate cancers. His research focuses on understanding the basic biology of these diseases and developing new ways to overcome resistance to treatments.

Friedlander earned his medical degree at New York University School of Medicine and completed a residency in internal medicine at UCSF. He received a Fulbright scholarship in 2006 to study medical ethics, and he completed a fellowship in hematology and oncology at UCSF, when he served as chief fellow. He has also received an American Society of Clinical Oncology Young Investigator Award.

Friedlander is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

  • Education

    New York University School of Medicine, 2003

  • Residencies

    UCSF Medical Center, Internal Medicine, 2006

  • Fellowships

    UCSF Medical Center, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages


With so many new options available for urologic cancers, my hope is that we can harness these treatments to help all our patients.

Where I see patients (2)

    My reviews


    Overall Experience
    110 Ratings
    About our process
    Oct 26, 2023
    Dr Friedlander is the best I've encountered!
    Jul 29, 2023
    Clear empathetic cutting edge knowledgeable admits not knowing and finds answers immediately inspires confidence
    Jun 10, 2023
    Dr. Friedlander is an amazing provider! He's caring thoughtful and consistent with his level of care! He truly puts the patient as first priority!
    May 25, 2023
    He is wonderful. Kind attentive skillful knowledgable easy to feel comfortable with him.
    May 11, 2023
    The best!
    Apr 04, 2023
    Dr. Friedlander had knew me for years. He communicates well and we have a very good rapport
    Mar 30, 2023
    I'm very satisfied with my care provider.
    Mar 30, 2023
    My experience with Dr Friedlander has always been excellent. He is thorough and caring. Couldn't ask for a better doctor.
    Mar 25, 2023
    Each doctor involved in my treatment has been superior.
    Mar 18, 2023
    Dr. Friedlander cares and knows bladder cancer. I'm lucky to have found an oncologist who's listens well.
    Jan 21, 2023
    He is great! Kind and caring and competent.
    Jan 19, 2023
    UCSF & Dr. Friedlander and his team take excellent care of me over the years.
    Jan 12, 2023
    Excellent in every way. Dr. Friedlander is a superb oncologist and I am very grateful.
    Nov 01, 2022
    First rate
    Sep 21, 2022
    We really enjoy and appreciate our calls with Dr. Freidlander!
    Sep 17, 2022
    Great! Profession skilled and caring!
    Aug 26, 2022
    I was very impressed with the visit.
    Aug 15, 2022
    Dr Friedlander was very professional courteous an explained every step of the procedures of my disease
    Jul 10, 2022
    Dr Friedlander is a superb physician- - outstanding clinical & interpersonal skills
    Jun 02, 2022
    I was amazed of everybody's concern for my condition they were very helpful very knowledgeable and very professional
    May 31, 2022
    I am a cancer patient receiving my primary care at another institution. I have contacted Dr. Friedlander as an expert second opinion on my case. In.this he is outstanding. He listens so well and he figures out at what level to talk to me so that it has maximum value to me.
    Apr 05, 2022
    Very thorough TX plan.
    Mar 17, 2022
    Dr.Friedlander is attentive extremely smart kind and empathetic.
    Feb 15, 2022
    Very good listener very patient with all my concerns. Dr. Friedlander is very very dedicated to the patient and he is never in a rush. Superb knowledge of his field.

    Selected research

    Decorative Caduceus

    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...

    Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.


    Decorative Caduceus

    Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

    The objective of this study to establish a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.